Screening for Parkinson's Disease

HS 2018-4408
Parkinsons, Movement disorders
Neal Hermanowicz, MD
UC Irvine campus in Irvine, Calif., and UC Irvine Medical Center in Orange, Calif.
The primary goal of this study is to see whether a screening process for Parkinson's disease can be successfully accomplished.

Inclusion requirements — you can participate in this study if:

  • You are a man or woman 50 years of age or older.
  • You are English speaking.
  • You have idiopathic constipation (fewer than three stools per week), gastroparesis (weakness of muscles in the stomach), irritable or inflammatory bowel disease (inflammation of digestive tract) with no underlying neurological diagnosis (brain disease).

Exclusion requirements — you cannot take part in this study if:

  • You are currently taking dopamine antagonist medications, or dopamine antagonist medications for 90 days prior to study screening. Dopamine antagonist medications include all antipsychotic medications, tetrabenazine (Xenazine), metoclopramide (Reglan) and prochlorperphenzaprine (Compazine).
  • You are currently taking 1-DOPA or dopamine agonist medications (bromocriptine, pramipexole, ropinirole, rotigotine).
  • You have a previous diagnosis of any neurological illness (brain disease).
  • You have had prior brain surgery.
Participation involves one visit to the research clinic (consent, questionnaires, clinical testing) that will take approximately 90 minutes or less. Additionally, a small number of study participants who meet specific criteria will be asked to undergo a DaTscan which takes approximately four hours.
There is no direct benefit anticipated for study participants. Participation in this research will contribute to the goal of finding a relatively simple screening tool for Parkinson’s disease.
This study involves no compensation to study participants.
Everlyne Gomez, UCI Department of Neurology, Clinical Trials Unit